Abstract
The authors describe a patient with personal and family history of muscle pains highly suggestive of mitochondrial disease. She presented with familial combined hyperlipidaemia with family history of premature coronary artery disease. After 4-week therapy of 5 mg of rosuvastatin once a week combined with 10 mg of ezetimibe daily, the low-density lipoprotein cholesterol level was markedly decreased from 3.88 to 2.82 mmol/l (27.3% reduction). She has experienced no adverse effects after 6 month treatment. The results suggest that the combination therapy of low-dose once-weekly rosuvastatin and daily ezetimibe could be used as an effective regimen for patients with mitochondrial disease.
MeSH terms
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / therapeutic use*
-
Azetidines / administration & dosage
-
Azetidines / therapeutic use*
-
Cholesterol, LDL / drug effects
-
Drug Therapy, Combination
-
Ezetimibe
-
Female
-
Fluorobenzenes / administration & dosage
-
Fluorobenzenes / therapeutic use*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / drug therapy*
-
Middle Aged
-
Mitochondrial Diseases / drug therapy*
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Rosuvastatin Calcium
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use*
-
Xanthomatosis / drug therapy*
Substances
-
Anticholesteremic Agents
-
Azetidines
-
Cholesterol, LDL
-
Fluorobenzenes
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Rosuvastatin Calcium
-
Ezetimibe
Supplementary concepts
-
Hyperlipemia with Familial Hypercholesterolemic Xanthomatosis